Navigation Links
VCU Massey Cancer Center finds new biomarker that predicts breast cancer relapse
Date:5/16/2011

Richmond, Va. (May 16, 2011) Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body's immune system that can predict a breast cancer patients' risk of cancer recurrence. This breakthrough may lead to new genetic testing that further personalizes breast cancer care.

The study, published in the journal Breast Cancer Research and Treatment, is the first to use tumor infiltrating immune cells located at the site of the tumor to predict cancer recurrence. Using tissue samples from breast cancer patients, researchers found that a specific, five-gene signature related to tumor infiltrating immune cells can accurately predict relapse-free survival. Currently, there are two main tests used to predict the risk of relapse in breast cancer patients, the Oncotype DX panel and the MammaPrint panel. Both of these tests focus on genes that are mainly expressed by tumor cells.

"We know that the body initiates an immune response when it detects cancer, and immune system cells are usually present at the site of the tumor," says the study's lead researcher, Masoud Manjili, D.V.M., Ph.D. assistant professor of microbiology and immunology at VCU Massey. "Our test differs from currently-used tests by looking for a biological response to the presence of cancer, and not relying on genes expressed by the actual cancer cells."

Tissue specimens were collected from female breast cancer patients and maintained in the VCU Massey Cancer Center Tissue & Data Acquisition and Analysis Core (TDAAC) over the past seven years. "We studied data from 17 patients. Of these patients, we had eight that relapsed within five years and nine that have remained cancer-free up to seven years," says Manjili. The five-gene signature was found to predict relapse in these patients with over 85 percent accuracy.

Manjili and his team will next study tissue samples from a larger patient sample to further validate the findings in this study. They also intend to test their findings in a long-term study of breast cancer patients undergoing treatment.

"Our findings could lead to clinical trials that test whether using immunotherapy prior to conventional treatments in breast cancer patients with a high risk of relapse could prime the patients' immune system, much like a vaccine, to prevent the likelihood of relapse," says Manjili.


'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. VCU Massey research finds new link between inflammation and cancer
2. Key leukemia defense mechanism discovered by VCU Massey Cancer Center
3. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
4. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
5. VCU Massey first to combine targeted agents to kill multiple myeloma cells
6. Enhancing arrest of cell growth to treat cancer in mice
7. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
8. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
9. Low forms of cyclin E reduce breast cancer drugs effectiveness
10. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
11. Soft drinks may increase risk of pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For Heroes ... lives in military battle for the country. The nonprofit Hope For Heroes partnered ... programs that empower independence for disabled military veterans, as well as police, firemen, and ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is a common ... long-term patient survival, reports a team of UPMC researchers in the largest study ... Journal of Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead ...
(Date:5/26/2016)... ... 2016 , ... MadgeTech will be showcasing its line of data logging ... at the MadgeTech headquarters. With products sold in more than 100 countries around the ... NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data ...
(Date:5/26/2016)... NY (PRWEB) , ... May 26, 2016 , ... ... Hereditary Retinal Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on June ... to the public. , Dr. Maisel, founder of Retina Group of New ...
(Date:5/26/2016)... ... May 26, 2016 , ... In an effort to provide hair restoration information to the ... users and those who do not use the app. Dr. Mohebi, the founder of Parsa ... Dr. Mohebi Live . , Dr. Mohebi says, “The positive response to the Snapchat ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
(Date:5/25/2016)...  Zymo Research Corp. announced today the final ... that help researchers obtain the most accurate and ... rapid growth of the study of microbiomes has ... methods to improve the reproducibility and quality of ... every step of the measurement process including collection ...
(Date:5/25/2016)... 2016  Granger Diagnostics today announced immediate availability of ... infections. This test ensures discovery of ALL bacteria, ... test requires only a simple swab of the wound ... G. Bostwick , MD, Chief Medical Officer, described ... "We are excited to make available, for the ...
Breaking Medicine Technology: